Overexpression of suppressor of zest 12 is associated with cervical node metastasis and unfavorable prognosis in tongue squamous cell carcinoma

Huijun Hu†, Yi Wang†, Zhongwu Li, Yumin Zhu, Wei Zhang, Dongmiao Wang, Tangyi Lin, Jianrong Yang, Yanling Wang and Jie Cheng

Abstract

**Objective:** Increased expression of suppressor of zest 12 (SUZ12), a core component of the polycomb repressive complex 2, contributes to human tumorigenesis and associates with patient prognosis. In the present study, we sought to investigate the expression of SUZ12 and its clinicopathological significance in primary tongue squamous cell carcinoma (TSCC).

**Methods:** The expression of SUZ12 protein was determined by immunohistochemistry in clinical samples from a retrospective cohort of 72 patients with primary TSCC who were treated at our institution from Jan. 2007 to Dec. 2013. The potential associations between SUZ12 abundance and multiple clinicopathological parameters were assessed by Chi square test. Moreover, the effect of SUZ12 expression on patients' survival was further estimated by Kaplan–Meier and Cox regression analyses.

**Results:** Our immunohistochemical staining data revealed aberrant overexpression of SUZ12 in a large subset of TSCC as compared to normal tongue mucosa. Elevated SUZ12 was found to be significantly associated with cervical nodes metastasis ($P = 0.0325$) and reduced overall as well as disease-free survival (Log-rank test, $P = 0.0225$, 0.0179, respectively). Both univariate and multivariate Cox regression analysis identified the expression status of SUZ12 (low/ high) as an important independent prognostic factor for patients’ survival.

**Conclusions:** Our data reveal that aberrant SUZ12 overexpression is associated with cervical nodes metastasis and reduced survival in TSCC. These findings suggest that SUZ12 might play critical roles during tongue tumorigenesis and serve as a novel biomarker with diagnostic and prognostic significance.

**Keywords:** SUZ12, Polycomb repressive complex, Tongue squamous cell carcinoma, Prognosis
underscore the highly aggressive nature of TSCC and the unresolved challenge for diagnostic and therapeutic management of this malignancy in the clinic. Until now, few biomarkers have been equivocally established for diagnostic and prognostic management of tongue cancer. Therefore, the identification of the new biomarkers and therapeutic targets for TSCC is paramount and urgent for clinicians to improve the patients’ prognosis.

Epigenetic abnormality is a hallmark of human cancer and greatly contributes to cancer initiation and progression [4]. Mounting evidence has established that several epigenetic modulators have been identified as key mediators driving tumorigenesis by serving as pro-oncogenes or tumor suppressor genes. Moreover, these epigenetic modulators hold great promise as putative therapeutic targets against cancer largely owing to their pervasive roles in gene regulation as well as the inherent reversible nature of epigenetic alternations [5]. Among these epigenetic modulators underlying tumorigenesis, several members of polycomb group (PcG) proteins have stood out as essential participators of malignant transformation as well as promising targets for cancer therapeutic intervention. Previous studies have revealed that the PcG components usually assemble in stable multi-protein complexes together with additional factors to maintain their target genes in a transcriptionally repressive state [6]. In brief, two polycomb repressive complexes (PRC1 and PRC2) harbor multiple core members to execute their functions by histone modifications and in turn induce gene silencing [7]. Our previous studies and others have offered strong evidence that multiple members of PcG such as Bmi1 and EZH2 are bona fide oncogenes contributing to tumorigenesis in diverse sites throughout the whole body including tongue and their overexpression associates with cancer aggressiveness and poor prognosis in a broad spectrum of human cancer including tongue cancer [8–10]. Notably, suppressor of zest 12 (SUZ12) is one of the core component of PRC2, which is essential for PRC2-mediated gene silencing by generating trimethylation on lysine 27 residue of histone H3 (H3K27me3) [11]. However, the biological roles and associated molecular mechanisms of SUZ12 underlying tumor development are just beginning to be elucidated. For example, SUZ12 has been found to be frequently overexpressed in several solid cancers including colorectal, ovarian and non-small lung cancer, etc. [12–14]. Furthermore, its aberrant overexpression commonly associated with tumor aggressive behaviors, advanced clinicopathological features and decreased survival, thus suggesting potential roles of SUZ12 as a novel cancer biomarker and a putative oncogene [12–14]. However, to the best of our knowledge, the expression of SUZ12 and its clinicopathological significance in TSCC have not been established yet.

Herein, we sought to investigate the expression of SUZ12 protein in primary human TSCC specimens and identify potential relationship between its abundance and clinicopathological features as well as patients’ survival.

Methods

Patients and tissue specimens

A retrospective cohort of 72 patients with primary TSCC treated at our institution between Jan. 2007 and Dec. 2013 were enrolled. Written informed consent was obtained from these patients. Patient inclusion criteria were described as follows: (1) primary TSCC without any prior history of surgery, chemotherapy or radiotherapy; (2) patients underwent radical tumor resection and neck dissection (elective or therapeutic neck dissection as required); (3) detailed information available including epidemiologic, clinical, pathological and follow-up data. The archived tissue samples were retrieved and haematoxylin–eosin staining slides for each patient were further analyzed to confirm the previous diagnose based on the established histopathological criteria. Fifteen samples of healthy tongue mucosa were obtained from other non-cancer surgeries and histologically confirmed under microscope by senior oral pathologists. This study protocol was reviewed and approved by the Research Ethic Committee of Nanjing Medical University (2015-0126).

Histopathological evaluation, clinicopathological categorization and immunohistochemical staining of SUZ12

The relevant clinicopathological parameters for each case including histological grade, TNM classification, clinical stage, etc. were determined similarly as we described before [8, 9, 15]. Immunohistochemical staining for SUZ12 was performed on 4-µm formalin-fixed, paraffin-embedded specimens using routine procedure. Briefly, tissue sections from representative paraffin blocks were deparaffinised in xylene and rehydrate through graded alcohols. Tissue slides were then processed in microwave heating in 10 mM citrate buffer (pH 6.0) for 15 min for antigen retrieval and 3% hydrogen peroxide for endogenous peroxidase inactivation. These sections were further incubated with primary antibody (anti-SUZ12, 1:200 dilution; Abcam, ab12073, USA) at 4 °C overnight and developed with 3,3′-diaminobenzidine and counterstained with haematoxylin. The immunoreactivity in each slide was assessed independently by two senior oral pathologists without knowledge about the relevant clinical and pathological data. Negative controls (without primary antibody incubation) were included in each staining run. Immunoreactivity was semi-quantitatively evaluated according to staining intensity and distribution using the immunoreactive score which was calculated as intensity.
score × proportion score as we reported previously [8, 15, 16]. Intensity score was defined as 0, negative; 1, weak; 2, moderate; 3, strong. The proportion score was defined as 0, negative; 1, <10%; 2, 11–50%; 3, 51–80%; 4, >80% positive cells. Therefore, the total score ranged from 0 to 12. Accordingly, the immunoreactivity of each slide was categorized into three subgroups based on the final score: 0, negative; 1–4, low expression; 4–12, high expression, similar as our previous reports [8, 15, 16].

Statistical analyses
The associations between SUZ12 expression and various clinicopathological parameters of patients were evaluated using Chi square test. The survival rates of patients were estimated using Kaplan–Meier method and compared with Log-rank test. The prognostic analyses were performed by univariate and multivariate Cox regression models to determine the individual clinicopathological variables with patients’ overall or disease-free survival. P values <0.05 (two-sided) were considered statistically significant. All statistical analyses were performed using Graphpad Prism 5 (La Jolla, CA, USA) or SPSS 18.0 (Armonk, NY, USA).

Results
Clinicopathological characteristics and SUZ12 expression in primary TSCC
Previous studies have provided clues to support the notion that SUZ12 is usually overexpressed in several human cancers and might serve as a putative protooncogene associated with tumorigenesis [12, 13]. To examine SUZ12 expression in TSCC, we evaluated the expression levels of SUZ12 protein by immunohistochemical staining in a retrospective cohort of 72 primary TSCC samples. The epidemiologic information and relevant clinicopathological features (age, gender, smoking, alcohol use, pathological grade, tumor size, clinical stage, cervical node status) of these patients included were summarized in Table 1. In brief, 40 male and 32 female patients were enrolled with mean age 56.5 years (31–81 years). The follow-up period ranged from 28 to 95 months with average 52.8 months. Based on our immunohistochemistry scoring regime, SUZ12 protein abundance in these primary TSCC and normal tongue epithelial samples (n = 15) was categorized, respectively. As shown in Table 2, SUZ12 levels in TSCC samples were graded as negative (4), low (31) and high (37) expression, respectively. In parallel, its expression levels in their normal counterparts were divided into negative (5), low (7) and high (3), respectively. These data showed significant difference of SUZ12 expression pattern between TSCC and normal tongue mucosa, and also clearly indicated that SUZ12 was aberrantly overexpressed in a significant fraction of primary TSCC. The representative immunohistochemical staining of SUZ12 in TSCC and normal tongue mucosa was shown in Fig. 1. High SUZ12 expression was mainly identified in the nucleus and much less in the cytoplasm in cancer cells, whereas weak staining was observed in normal tongue epithelial cells. The detailed associations between SUZ12 expression and clinicopathological variables were further analyzed and shown in Table 1. There were no significant correlations between SUZ12 expression with patients’ gender, age, smoking, alcohol use, tumor size, pathological grade and clinical stage. However, significant association between SUZ12 abundance with cervical nodes metastasis was found with P value 0.0325 (Chi square test).

SUZ12 expression associates with TSCC patients’ survival
To reveal the potential prognostic value of SUZ12 expression in TSCC, we then attempted to evaluate the correlation between SUZ12 expression and patients’ survival.

| Clinicopathological parameters | Cases | SUZ12 Lowa | SUZ12 High | P values |
|-------------------------------|-------|------------|-----------|---------|
| Gender | 35 37 0.486 | 35 37 0.486 | 35 37 0.486 |  |
| Male | 40 21 19 | 40 21 19 | 40 21 19 |  |
| Female | 32 14 18 | 32 14 18 | 32 14 18 |  |
| Age | 40 21 19 0.3429 | 40 21 19 0.3429 | 40 21 19 0.3429 |  |
| <60 | 40 21 19 | 40 21 19 | 40 21 19 |  |
| >60 | 32 14 18 | 32 14 18 | 32 14 18 |  |
| Smoking | 37 19 18 0.6324 | 37 19 18 0.6324 | 37 19 18 0.6324 |  |
| No | 40 22 18 0.2253 | 40 22 18 0.2253 | 40 22 18 0.2253 |  |
| Yes | 32 13 19 | 32 13 19 | 32 13 19 |  |
| Alcohol use | 37 19 18 0.6324 | 37 19 18 0.6324 | 37 19 18 0.6324 |  |
| No | 40 22 18 0.2253 | 40 22 18 0.2253 | 40 22 18 0.2253 |  |
| Yes | 32 13 19 | 32 13 19 | 32 13 19 |  |
| Tumor size | 37 19 18 0.6324 | 37 19 18 0.6324 | 37 19 18 0.6324 |  |
| T1–T2 | 58 29 29 0.7683 | 58 29 29 0.7683 | 58 29 29 0.7683 |  |
| T3–T4 | 14 6 8 | 14 6 8 | 14 6 8 |  |
| Pathological grade | 32 19 13 0.1542 | 32 19 13 0.1542 | 32 19 13 0.1542 |  |
| I | 40 16 24 | 40 16 24 | 40 16 24 |  |
| II–III | 32 19 13 0.1542 | 32 19 13 0.1542 | 32 19 13 0.1542 |  |
| Cervical node metastasis | 32 19 13 0.1542 | 32 19 13 0.1542 | 32 19 13 0.1542 |  |
| N(0) | 38 23 15 0.0325 | 38 23 15 0.0325 | 38 23 15 0.0325 |  |
| N(+)| 34 12 22 | 34 12 22 | 34 12 22 |  |
| Clinical stage | 32 19 13 0.1542 | 32 19 13 0.1542 | 32 19 13 0.1542 |  |
| I–II | 32 19 13 0.1542 | 32 19 13 0.1542 | 32 19 13 0.1542 |  |
| III–IV | 36 14 22 | 36 14 22 | 36 14 22 |  |

The number in italic indicate statistical significance with p values <0.05

*a Both of patients with low and negative SUZ12 staining are stratified into low SUZ12 category for simplicity.
Until the last follow-up, 41 of 72 (56.9%) patients were alive and disease-free, 6 (8.3%) patients alive but with recurrence and/or cervical nodal metastases, 25 (34.7%) patients dying due to local recurrence, metastases, or other unrelated diseases. The results from Kaplan–Meier survival analyses indicated that high SUZ12 expression had an adverse prognostic impact on patients’ outcomes. In detail, as shown in Fig. 2, high SUZ12 abundance significantly associated with reduced overall survival and disease-free survival (Log-rank, \( P = 0.0225 \), 0.0179, respectively).

To further assess the clinical significance of SUZ12 expression as a prognostic predictor for patients with TSCC, the univariate and multivariate survival analyses (Cox proportional hazards regression model) were performed. As indicated in Table 3, the univariate survival analysis revealed that SUZ12 expression status and cervical node metastasis were significantly associated with overall survival (hazard ratio [HR] 3.023; 95% confidence interval [95% CI] 1.216–7.516; \( P = 0.017 \) for SUZ12; HR 1.759; 95% CI 1.240–3.291; \( P = 0.042 \) for cervical node metastasis, respectively), while other clinicopathological variable didn’t reach the statistical significance. To rule out the confounding factors, multivariate survival analysis was performed. In this Cox regression model, only the SUZ12 expression status was identified as an independent prognostic marker for the overall survival of patients with TSCC (HR 2.848; 95% CI 1.121–7.240; \( P = 0.028 \)).

**Discussion**

The epigenetic modifiers, PRC1 and 2, regulate gene expression by modifying chromatin structure and are intricately implicated in various biological and pathological processes including stem cell plasticity, cell differentiation and proliferation as well as tumorigenesis [6, 17, ...
Previous studies have suggested that the SUZ12, one of the core components of PRC2, might be an oncogene driving tumorigenesis and serve as a novel diagnostic biomarker and therapeutic target for cancer treatment [13, 18, 19]. Herein we investigated the expression pattern of SUZ12 in primary TSCC and determined its clinicopathological relevance and prognostic significance for patients with TSCC. Our findings reveal that SUZ12 is aberrantly overexpressed in a significant fraction of TSCC and its overexpression associates with aggressive clinicopathological features and unfavorable prognosis.

Tongue tumorigenesis in human is characterized by multiple and consecutive histopathological stages from normal epithelial to invasive SCC which is driven by oncogenes activation and tumor suppressor inactivation [2]. In particular, epigenetic inactivation of tumor suppressor genes contributes to initiation and progression of tongue cancer [20]. Among them, these chromatin modifiers like the polycomb members have been increasingly recognized as key players during tumorigenesis. They usually facilitate cancer initiation, overgrowth and metastasis, and also have been identified as therapeutic targets with remarkable translational potential [21]. We and others have provided evidence that several members of PcG such as EZH2 and Bmi1 are aberrantly upregulated in tongue cancer and associated with aggressiveness and poor prognosis [8, 10]. Notably, highly elevated SUZ12 has been found in bladder, gastric, non-small cell lung and colorectal cancer, etc. [12, 13, 19]. In line with these previous finding, our data reveal that SUZ12 is significantly elevated in a large subset of human TSCC, thus supporting the notion that SUZ12 might be a bona fide oncogene fostering tumorigenesis in diverse sites throughout the body including tongue. To the best of our knowledge, this might be the first study to uncover the abnormal expression pattern of SUZ12 in TSCC.

**Table 3** Univariate and multivariate survival analyses for patients with primary TSCC using proportional hazards methods

| Variable                   | Univariate survival analysis | Multivariate survival analysis |
|----------------------------|------------------------------|--------------------------------|
|                            | Hazard ratio  95% CI         | P value | Hazard ratio 95% CI | P value |
| Gender (male, female)      | 1.651 (0.739–3.688)         | 0.221   | 1.428 (0.599–3.405) | 0.422   |
| Age (≤60, >60)             | 0.753 (0.338–1.680)         | 0.489   | 1.374 (0.601–3.141) | 0.452   |
| Smoking (no, yes)          | 1.253 (0.653–1.835)         | 0.524   | 1.372 (0.665–1.732) | 0.536   |
| Alcohol use (no, yes)      | 1.121 (0.547–1.538)         | 0.753   | 1.231 (0.557–1.861) | 0.643   |
| Tumor size (T1–T2, T3–T4) | 1.331 (0.528–3.357)         | 0.544   | 1.447 (0.505–4.147) | 0.491   |
| Pathological grade (I, II–III) | 1.258 (0.490–1.994)     | 0.117   | 1.246 (0.444–3.496) | 0.676   |
| Cervical nodal metastasis (N0, N+) | 1.759 (1.240–3.291) | 0.042   | 1.696 (1.104–3.067) | 0.056   |
| Clinical stage (I–II, III–IV) | 1.203 (0.688–1.824) | 0.095   | 0.922 (0.524–1.622) | 0.778   |
| SUZ12 expression (low, high) | 3.023 (1.216–7.516) | 0.017   | 2.848 (1.121–7.240) | 0.028   |

The numbers in italics indicate statistical significance with p values <0.05

*a* Both of patients with low and negative SUZ12 staining are stratified into low SUZ12 category for simplicity

![Fig. 2](image-url) Kaplan–Meier graphs representing the probability of TSCC patients’ survival based on SUZ12 expression status. **a** High SUZ12 expression is significantly associated with reduced overall survival in TSCC patients. P value from Log-rank test is shown. **b** High SUZ12 expression is significantly associated with reduced disease-free survival in TSCC patients. P value from Log-rank test is shown.
However, due to the limited number of patients enrolled here, more number of patients from multiple institutions is needed to definitively establish the overexpression pattern of SUZ12 as well as its diagnostic utility in tongue cancer.

Accumulating evidence has demonstrated that SUZ12 overexpression significantly associated with aggressiveness in multiple human cancers [13]. For example, elevated SUZ12 is significantly associated with tumor size, lymph node metastasis and clinical stages in non-small cell lung cancer and colorectal cancer [13, 14]. Similarly, our findings reveal that SUZ12 overexpression significantly associates with cervical lymph nodes metastasis in TSCC, while the associations between other clinicopathological parameters and SUZ12 don’t reach statistical significance. Noticeably, Our findings and others point to an interesting link and positive association between SUZ12 expression and cancer metastasis irrespective of cancer origin and primary site [13, 22, 23]. Complementary to this notion, previous studies have demonstrated that the metastasis-regulator Snail recruits SUZ12 to the CDH1 promoter and represses E-cadherin expression, thus in turn triggers EMT and cancer metastasis [24, 25]. Moreover, targeting SUZ12 by gene knockdown suppresses the migratory and invasive properties of cancer cells and inhibits tumor metastasis in animal models [13, 25]. Taken together, we propose that SUZ12 is a novel cancer biomarker of TSCC which significantly associates with cervical node metastasis. It remains an interesting question to determine the expression level of SUZ12 in the metastatic lesions and its clinical significance, and further unravel its associated mechanistic underpins during cancer metastatic spread.

The past decades have witnessed tremendous progress in diagnosis and treatment for TSCC. However, the 5-year survival rate remains disappointing, suggesting that accurate prognostic prediction is a great challenge but highly beneficial in the clinic [3]. Previous studies have revealed that SUZ12 expression associates with patients’ prognosis and is identified as a key independent prognostic predictor for patients with epithelial ovarian cancer, non-small cell lung cancer and gastric cancer [12, 13]. For example, Li et al. [12] have reported that expression of SUZ12 positively correlates with Ki67 and predicts shorter overall survival in patients with ovarian cancer. Consistent with these findings, our results indicate that patients with high SUZ12 have significantly shorter survival as compared to those with low SUZ12. Furthermore, SUZ12 expression is identified as an independent prognostic factor affecting survival of patients with TSCC. Thus, the expression status of SUZ12 might offer valuable information about patients’ prognosis and indication for effective follow-up management.

A line of evidence has uncovered that SUZ12 is critically involved in tumorigenesis by promoting cell proliferation, migration and metastasis while suppressing apoptosis [12, 13, 25]. Moreover, SUZ12 together with miR-200b is important for cancer stem cell growth and invasive ability in breast cancer cells [26]. In particular, pharmacologic or genetic disruption of SUZ12 inhibited cell proliferation and invasion, and disrupted the maintenance of cancer stem cell both in vitro and in vivo [12, 13, 26, 27]. These abovementioned findings strongly suggest that SUZ12 serves as not only a novel cancer biomarker with diagnostic and prognostic values, but also a viable therapeutic target. Therefore, it remains an open and interesting question to unravel the roles of SUZ12 and its regulatory network during tongue tumorigenesis and to develop efficient approaches to therapeutically targeting SUZ12 in cancer.

Conclusions

In conclusion, our data reveal that SUZ12 is aberrantly overexpressed in a significant fraction of TSCC and might serve as a novel cancer biomarker as well as therapeutic target for tongue cancer. More studies are warranted to further unravel the mechanistic insights of SUZ12 dysregulation during the initiation and progression of TSCC.

Abbreviations

SUZ12: suppressor of zest 12; PRC2: polycomb repressive complex 2; TSCC: tongue squamous cell carcinoma; HPV: human papillomavirus; OSCC: oral squamous cell carcinoma; PcG: polycomb group; H3K27me3: trimethylation on lysine 27 residue of histone H3; HR: hazard ratio; 95% CI: 95% confidence interval.

Authors’ contributions

HH and YW performed the experimental study, data collection and analysis and manuscript writing. ZL, YZ and WZ analyzed the IHC data. DW, TL, JY and YW performed surgery and collected the data of patients. JC conceived and supervised the whole project. All authors read and approved the final manuscript.

Author details

1 Jiangsu Key Laboratory of Oral Diseases, Nanjing Medical University, Nanjing 210029, People's Republic of China. 2 Department of Oral and Maxillofacial Surgery, Affiliated Stomatological Hospital, Nanjing Medical University, 136, Hanzhong Road, Nanjing 210029, People's Republic of China. 3 Department of Oral Pathology, Affiliated Stomatological Hospital, Nanjing Medical University, Nanjing 210029, People's Republic of China.

Acknowledgements

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

All original data are available upon request.

Consent for publication

No parts of this manuscript are being considered for publication elsewhere.
Ethics approval and consent to participate
Our study protocol was reviewed and approved by the Research Ethic Committee of Nanjing Medical University (2016-126). Written informed consent was obtained from all subjects in our study.

Funding
This work is financially supported, in whole or in part, by National Natural Science Foundation of China (81572669, 81602386), Natural Science Foundation of Jiangsu Province (BK20151561, BK20161564, BK20161024), A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (2014-37) and Qing-Lan Project.

Received: 30 August 2016   Accepted: 4 February 2017
Published online: 13 February 2017

References
1. Chi AC, Day TA, Neville BW. Oral cavity and oropharyngeal squamous cell carcinoma—an update. CA Cancer J Clin. 2015;65(5):401–21.
2. Scully C, Bagan J. Oral squamous cell carcinoma overview. Oral Oncol. 2009;45(4–5):301–8.
3. Bello IO, Soini Y, Salo T. Prognostic evaluation of oral tongue cancer: means, markers and perspectives (II). Oral Oncol. 2010;46(9):636–43.
4. Suva ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science. 2013;339(6127):1567–70.
5. Popovic R, Licht JD. Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov. 2012;2(5):405–13.
6. Simon JA, Kingston RE. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol. 2009;10(10):697–708.
7. Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature. 2011;469(7330):343–9.
8. Li Z, Wang Y, Qiu J, Li Q, Yuan C, Zhang W, Wang D, Ye J, Jiang H, Yang J, et al. The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer. Oncotarget. 2013;4(12):2532–49.
9. Li Z, Wang Y, Yuan C, Zhui Y, Qiu J, Zhang W, Qi B, Wu H, Ye J, Jiang H, et al. Oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer. Lab Invest. 2014;94(12):1431–45.
10. He Q, Liu Z, Zhao T, Zhao L, Zhou X, Wang A. Bmi1 drives stem-like properties and is associated with migration, invasion, and poor prognosis in tongue squamous cell carcinoma. Int J Biol Sci. 2015;11(1):1–10.
11. Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED–EZH2 complex. Mol Cell. 2004;15(1):57–67.
12. Li H, Cai Q, Wu H, Vathipadiekal V, Doobin ZC, Li T, Hua X, Landen CN, Birrer MJ, Sanchez-Beato M, et al. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK. Mol Cancer Res. 2012;10(11):1462–72.
13. Liu C, Shi X, Wang L, Wu Y, Jin F, Bai C, Song Y. SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis. Tumour Biol. 2014;35(6):6073–82.
14. Liu YL, Gao X, Jiang Y, Zhang G, Sun ZC, Cui BB, Yang YM. Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer. J Cancer Res Clin Oncol. 2015;141(4):661–9.
15. Liu LK, Jiang YY, Zhou XX, Wang DM, Song XL, Jiang HB. Upregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome. Mod Pathol. 2010;23(2):213–24.
16. Wang D, Zhu Y, Wang Y, Li Z, Yuan C, Zhang W, Yuan H, Ye J, Yang J, Jiang H, et al. The pluripotency factor LIN28B is involved in oral carcinogenesis and associates with tumor aggressiveness and unfavorable prognosis. Cancer Cell Int. 2015;15:99.
17. Pasini D, Di Croce L. Emerging roles for polycomb proteins in cancer. Curr Opin Genet Dev. 2016;36:50–8.
18. Sauvageau M, Sauvageau G. Polycomb group proteins: multifaceted regulators of somatic stem cells and cancer. Cell Stem Cell. 2010;7(3):299–313.
19. Lee SR, Roh YG, Kim SK, Lee JS, Seol SY, Lee HH, Kim WT, Kim JW, Heo J, Cha HJ, et al. Activation of EZH2 and SUZ12 regulated by EZF1 predicts the disease progression and aggressive characteristics of bladder cancer. Clin Cancer Res. 2015;21(23):S391–403.
20. Gonzalez-Ramirez I, Soto-Reyes E, Sanchez-Perez Y, Herrera LA, Garcia-Cuellar C. Histones and long non-coding RNAs: the new insights of epigenetic deregulation involved in oral cancer. Oral Oncol. 2014;50(8):691–5.
21. Jithesh PV, Risk JM, Schache AG, Dhandha J, Lane B, Liloglou T, Shaw RJ. The epigenetic landscape of oral squamous cell carcinoma. Br J Cancer. 2013;108(2):370–9.
22. Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F, Liu Y. TGFB-beta-induced upregulation of malat1 promotes bladder cancer metastasis by associating with suz12. Clin Cancer Res. 2014;20(6):1531–41.
23. Peng F, Jiang J, Yu Y, Tian R, Guo X, Li X, Shen M, Xu M, Zhu F, Shi C, et al. Direct targeting of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma tumourigenesis and metastasis. Br J Cancer. 2013;109(10):2092–104.
24. Herranz N, Pasini D, Diaz-VM, Franci C, Gutierrez A, Dave N, Escriva M, Hernandez-Munoz I, Di Croce L, Helin K, et al. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol Cell Biol. 2008;28(15):4772–81.
25. Xia R, Jin FY, Lu K, Wan L, Xie M, Xu TP, De W, Wang ZX. SUZ12 promotes gastric cancer cell proliferation and metastasis by regulating KLF2 and E-cadherin. Tumour Biol. 2015;36(7):5341–51.
26. Ilipoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K. Loss of mir-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell. 2010;39(5):761–72.
27. Crea F, Hurt EM, Mathews LA, Cabarcas SM, Sun L, Marquez VE, Danesi R, Farrar WL. Pharmacologic disruption of polycomb repressive complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer. 2011;10(40).